Welcome Guest to Happi

Subscribe Free: Magazine | eNewsletter

current issue October 2014
 •  Brilliant Group Opens California Facility  •  DSM Appoints Bathany-Di Mascio  •  L'Oreal USA To Buy Carol's Daughter  •  Register Now for 2015 ACI Convention  •  Palmer’s Skin Success Adds Retinol
Print

Takasago Investing $10 Million In Chennai Site



Published January 30, 2013
Related Searches: sales international men president
Post a comment
INDIA: Takasago International (Singapore) Pte. Ltd., the regional subsidiary of publicly listed Takasago International Corp, will invest $10 million to set up a new manufacturing and research facility in Chennai, Tamil Nadu.

The new Indian facility, which will start operations in the first quarter of 2014, is part of Takasago’s goal of developing key creation, application, sensory, R&D and manufacturing capabilities for new flavors and fragrances customized for this region. This investment follows a $32 million investment in a new facility in Singapore as part of its regional expansion strategy.

“Takasago has set itself the goal of becoming a world-class flavors and fragrances company in the run-up to its centennial in 2020,” said Ritaro Igaki, president and CEO, Takasago International Corp. “We are strengthening Takasago’s organization and expanding our operations, and this investment commitment is a key example that will help us achieve our ambition.”

The new manufacturing operation in India will sit on five acres of land. Construction on the site will begin in Q2 2013 and operations will start in Q1 2014. The facility, when fully operational, will become the headquarters for all of Takasago’s research, manufacturing and sales operations in India.

Newly appointed Rajendra P. Ghogale, managing director of Takasago International India, added, “Takasago is developing its operations in India with a key focus on sustainability. Takasago will concentrate on several key segments, bring in innovative technology, and offer creative solutions and value to our customers.”


blog comments powered by Disqus